Ctrl

K

Ripretinib

Class
Targeted therapy
Subclass
Tyrosine kinase inhibitors
Generic name
Ripretinib
Brand names
Qinlock®
Common formulations
Tablet
Dosage and administration
Adults patients
Treatment of gastrointestinal stromal tumors • Unresectable, metastatic
•
150 mg PO daily until disease progression or unacceptable toxicity
Indications for use
Labeled indications
Adults
•
Treatment of gastrointestinal stromal tumors (unresectable, metastatic)
Pregnancy and breastfeeding
Breastfeeding
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource